New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

ORLANDO, Fla. — In moderate to severe plaque psoriasis, two highly selective oral TYK2 inhibitors produced a level of response in phase 2 studies suggesting that drugs in this class might rival ...

Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...

(RTTNews) - Johnson & Johnson (JNJ) announced new icotrokinra (JNJ-2113) data from its Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis (PsO ...